Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal.

Literature DB >> 25666750

Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal.

Suoyuan Li¹, Wei Sun, Hongsheng Wang, Dongqing Zuo, Yingqi Hua, Zhengdong Cai.

Abstract

Osteosarcoma (OS) is the most common and aggressive primary malignant type of bone cancer in children and adolescents. Chemotherapy is one of the most important treatments for OS. Although cancer therapy has improved over the past few decades, survival outcomes for OS patients remain unsatisfactory. One of the primary reasons for the failure of current treatments is that patients with stage IV cancer often develop resistance to anticancer agents. This article will review multidrug resistance (MDR) mechanisms of OS and strategies for overcoming resistance.

Entities: Disease Species

Mesh：

Substances：
Antineoplastic Agents

Year: 2015 PMID： 25666750 DOI： 10.1007/s13277-015-3181-0

Source DB: PubMed Journal: Tumour Biol ISSN： 1010-4283

89 in total

1. Gallic acid inhibits migration and invasion in human osteosarcoma U-2 OS cells through suppressing the matrix metalloproteinase-2/-9, protein kinase B (PKB) and PKC signaling pathways.

Authors: Ching-Lung Liao; Kuang-Chi Lai; An-Cheng Huang; Jai-Sing Yang; Jen-Jyh Lin; Shin-Hwar Wu; W Gibson Wood; Jaung-Geng Lin; Jing-Gung Chung
Journal: Food Chem Toxicol Date: 2012-02-25 Impact factor: 6.023

2. Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy.

Authors: J Z Li; Z Q Tian; S N Jiang; T Feng
Journal: Genet Mol Res Date: 2014-04-25

3. Protein kinase C regulates ezrin-radixin-moesin phosphorylation in canine osteosarcoma cells.

Authors: S-H Hong; T Osborne; L Ren; J Briggs; C Mazcko; S S Burkett; C Khanna
Journal: Vet Comp Oncol Date: 2010-12-14 Impact factor: 2.613

Review 4. Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy.

Authors: Dietrich Keppler
Journal: Handb Exp Pharmacol Date: 2011

5. Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma.

Authors: H Tsuchiya; Y Mori; Y Ueda; G Okada; K Tomita
Journal: Anticancer Res Date: 2000 Jan-Feb Impact factor: 2.480

6. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.

Authors: Paul A Meyers; Cindy L Schwartz; Mark D Krailo; John H Healey; Mark L Bernstein; Donna Betcher; William S Ferguson; Mark C Gebhardt; Allen M Goorin; Michael Harris; Eugenie Kleinerman; Michael P Link; Helen Nadel; Michael Nieder; Gene P Siegal; Michael A Weiner; Robert J Wells; Richard B Womer; Holcombe E Grier
Journal: J Clin Oncol Date: 2008-02-01 Impact factor: 44.544

7. Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity.

Authors: Ilan Ifergan; Issac Meller; Josefin Issakov; Yehuda G Assaraf
Journal: Cancer Date: 2003-11-01 Impact factor: 6.860

8. Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925.

Authors: X Yang; P Yang; J Shen; E Osaka; E Choy; G Cote; D Harmon; Z Zhang; H Mankin; F J Hornicek; Z Duan
Journal: Br J Cancer Date: 2014-05-22 Impact factor: 7.640

9. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.

Authors: Ymera Pignochino; Giovanni Grignani; Giuliana Cavalloni; Manuela Motta; Marta Tapparo; Stefania Bruno; Alessia Bottos; Loretta Gammaitoni; Giorgia Migliardi; Giovanni Camussi; Marco Alberghini; Bruno Torchio; Stefano Ferrari; Federico Bussolino; Franca Fagioli; Piero Picci; Massimo Aglietta
Journal: Mol Cancer Date: 2009-12-10 Impact factor: 27.401

10. miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.

Authors: Yong Zhou; Zufa Huang; Song Wu; Xiaofang Zang; Min Liu; Jian Shi
Journal: J Exp Clin Cancer Res Date: 2014-01-27

40 in total

Review 1. Progress in the chemotherapeutic treatment of osteosarcoma.

Authors: Ya Zhang; Jingqing Yang; Na Zhao; Cao Wang; Santosh Kamar; Yonghong Zhou; Zewei He; Jifei Yang; Bin Sun; Xiaoqian Shi; Lei Han; Zuozhang Yang
Journal: Oncol Lett Date: 2018-09-12 Impact factor: 2.967

2. Hypoxia promotes chemotherapy resistance by down-regulating SKA1 gene expression in human osteosarcoma.

Authors: Qiong Ma; Yinglong Zhang; Tao Liu; Kuo Jiang; Yanhua Wen; Qingyu Fan; Xiuchun Qiu
Journal: Cancer Biol Ther Date: 2017-02-17 Impact factor: 4.742

3. The predictive potential and oncogenic effects of HOXC8 expression on osteosarcoma.

Authors: Li Cheng; Xiaojie Wei; Keqi Zhao; Fenzan Wu; Wenjie Lu; Songlin Tong; Guanzhen Yu
Journal: Tumour Biol Date: 2016-09-20

Review 4. Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.

Authors: Ingrid Lilienthal; Nikolas Herold
Journal: Int J Mol Sci Date: 2020-09-19 Impact factor: 5.923